Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Chan, S. L.; Kudo, M.; Sangro, B.; Kelley, R. K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; Cheng, A. L.; Azevedo, S.; Reig Monzon, M. E.; Assenat, E.; Yarchoan, M.; He, A. R.; Makowsky, M.; Gupta, C.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | ESMO Asia Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2022 Dec 2-4 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-11-01 |
| Start Page: | S1456 |
| Language: | English |
| ACCESSION: | WOS:000897943700068 |
| DOI: | 10.1016/j.annonc.2022.10.103 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 67O -- Source: Wos |
